Altiratinib Terminated Phase 1 Trials for Locally Advanced Tumors / Metastatic Solid Neoplasm / Cancers With MET Genomic Alterations / Cancers With TRK Genomic Alterations Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02228811A Study of DCC-2701 in Participants With Advanced Solid Tumors